Application of microbiome management in therapy for clostridioides difficile infections: From fecal microbiota transplantation to probiotics to microbiota-preserving antimicrobial agents

Chun Wei Chiu, Pei Jane Tsai, Ching Chi Lee, Wen Chien Ko, Yuan Pin Hung

研究成果: Review article同行評審

1 引文 斯高帕斯(Scopus)

摘要

Oral vancomycin and metronidazole, though they are the therapeutic choice for Clostrid-ioides difficile infections (CDIs), also markedly disturb microbiota, leading to a prolonged loss of colonization resistance to C. difficile after therapy; as a result, their use is associated with a high treatment failure rate and high recurrent rate. An alternative for CDIs therapy contains the delivery of beneficial (probiotic) microorganisms into the intestinal tract to restore the microbial balance. Recently, mixture regimens containing Lactobacillus species, Saccharomyces boulardii, or Clostridium butyricum have been extensively studied for the prophylaxis of CDIs. Fecal microbiota transplantation (FMT), the transfer of (processed) fecal material from healthy donors to patients for treating CDIs, combined with vancomycin was recommended as the primary therapy for multiple recurrent CDIs (rCDIs). Either probiotics or FMT have been utilized extensively in preventing or treating CDIs, aiming at less disturbance in the microbiota to prevent rCDIs after therapy cessation. Otherwise, many newly developed therapeutic agents have been developed and aim to preserve microbiota during CDI treatment to prevent disease recurrence and might be useful in clinical patients with rCDIs in the future.

原文English
文章編號649
期刊Pathogens
10
發行號6
DOIs
出版狀態Published - 2021 六月

All Science Journal Classification (ASJC) codes

  • 免疫學和過敏
  • 分子生物學
  • 免疫學與微生物學 (全部)
  • 微生物學(醫學)
  • 傳染性疾病

指紋

深入研究「Application of microbiome management in therapy for clostridioides difficile infections: From fecal microbiota transplantation to probiotics to microbiota-preserving antimicrobial agents」主題。共同形成了獨特的指紋。

引用此